The Journal of Precision Medicine

About adminpmls2016

This author has not yet filled in any details.
So far adminpmls2016 has created 49 blog entries.

Agilent Announces New SureSelect Human All Exon V8

2021-06-04T13:53:57-05:00June 4th, 2021|

Agilent Technologies Inc. (NYSE: A) today announced the release of SureSelect Human All Exon V8 – a new exome design that provides comprehensive content and up-to-date coverage of protein-coding regions from RefSeq, CCDS, and GENCODE. It also covers the TERT promoter and hard-to-capture exons that are omitted by other exomes on the market. The [...]

New Research from Caris Life Sciences Finds Immunotherapy Resistance in Leiomyosarcoma

2021-06-04T13:36:10-05:00June 4th, 2021|

Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, to present findings that provide a deeper understanding of how immunotherapies (IO) affect leiomyosarcoma (LMS), a rare cancer that affects smooth muscle tissue, through the use of whole exome and whole transcriptome sequencing. These [...]

Labcorp to Introduce Combined Oncology Offering at 2021 ASCO® Annual Meeting

2021-06-04T13:31:37-05:00June 4th, 2021|

Labcorp (NYSE: LH), a leading global life sciences company, today announced the introduction of its combined Labcorp oncology platform at the virtual 2021 American Society of Clinical Oncology (ASCO®) Annual Meeting held June 4-8. Labcorp’s oncology platform brings together the company’s leadership in diagnostic testing with its comprehensive drug development services, delivering targeted solutions [...]

Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC

2021-06-04T13:27:57-05:00June 4th, 2021|

Novartis today announced the first published mature overall survival (OS) and updated overall response rate (ORR) data following treatment with Tabrecta® (capmatinib) in adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping (METex14)1-3. Data from the ongoing, pivotal, multi-cohort Phase II GEOMETRY [...]

Bristol Myers Squibb Presents Data from CheckMate -648

2021-06-04T13:24:13-05:00June 4th, 2021|

Bristol Myers Squibb (NYSE: BMY) today announced results from the Phase 3 CheckMate -648 trial, in which two Opdivo-based treatment combinations — Opdivo (nivolumab)plus chemotherapy and Opdivo plus Yervoy (ipilimumab) —demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit compared to chemotherapy at the pre-specified interim analysis in patients with unresectable advanced or [...]

PrecisionLife and Cyclica Sign Strategic Partnership Combining Leading Data-driven Biology and Chemistry Platforms to Create a Rapid Innovation Engine for Drug Discovery

2021-05-17T08:51:06-05:00May 17th, 2021|

PrecisionLife Ltd. (“PrecisionLife”), the leading combinatorial analytics company driving understanding of disease biology and patient stratification, and Cyclica Inc. (“Cyclica”), the partner of choice for data-driven drug discovery, announce that they have entered into a strategic partnership to co-market and offer their complementary computational platforms as an integrated drug discovery factory. The companies will initially [...]

Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed.

2021-04-29T12:29:27-05:00April 29th, 2021|

Basel, April 27, 2021 - commenting on the quarter, Vas Narasimhan, CEO of Novartis, said: “Novartis growth drivers and launches continued their strong momentum with double-digit growth for Entresto, Cosentyx, Oncology growth drivers and Zolgensma. We expect Sandoz performance to stabilize, in the near-term, after a challenging quarter. Our broad pipeline of novel medicines continued [...]

Geisinger awarded $3.6 million to study genetics of cancer

2021-04-29T12:07:14-05:00April 29th, 2021|

The National Cancer Institute (NCI), part of the National Institutes of Health, has awarded a 5-year, $3.6 million contract to Geisinger to study the role of genetic variation in cancer. Researchers from Geisinger and the NCI’s Division of Cancer Epidemiology and Genetics (DCEG) will analyze genetic data from Geisinger’s MyCode Community Health Initiative, a precision [...]

Thermo Fisher Scientific Reports First Quarter 2021 Results

2021-04-29T12:05:32-05:00April 29th, 2021|

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended April 3, 2021. First Quarter 2021 Highlights First quarter revenue increased 59% to $9.91 billion. First quarter GAAP diluted earnings per share (EPS) increased 198% to $5.88. First quarter adjusted EPS increased 145% to $7.21. Continued significant [...]

Illumina to Donate US $60 Million in Sequencing Capabilities to Establish a Global Pathogen Genomics Initiative

2021-04-29T12:02:23-05:00April 29th, 2021|

SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NASDAQ: ILMN) has committed US $60 million in sequencing capabilities to a global pathogen genomics initiative, in partnership with the Bill & Melinda Gates Foundation and other public and private entities. The initiative expands on the Africa Pathogen Genomics Initiative (Africa PGI) announced in October 2020, and will help create [...]

Go to Top